Delayed
Australian S.E.
07:29:55 27/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.017
AUD
|
0.00%
|
|
-5.56%
|
+54.55%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
23.11
|
27.06
|
54.17
|
21.97
|
24.95
|
10.37
|
Enterprise Value (EV)
1 |
15.53
|
19.39
|
50.95
|
17.22
|
26.45
|
11.74
|
P/E ratio
|
-6.76
x
|
-5.35
x
|
-9.61
x
|
-3
x
|
-3.58
x
|
-0.44
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.88
x
|
10.6
x
|
-
|
628
x
|
11.7
x
|
4.87
x
|
EV / Revenue
|
2.61
x
|
7.59
x
|
-
|
492
x
|
12.4
x
|
5.51
x
|
EV / EBITDA
|
-4.8
x
|
-4.92
x
|
-8.75
x
|
-2.6
x
|
-3.37
x
|
-1.65
x
|
EV / FCF
|
-10.2
x
|
-6.01
x
|
-37
x
|
-6.57
x
|
-6.2
x
|
7.97
x
|
FCF Yield
|
-9.84%
|
-16.6%
|
-2.7%
|
-15.2%
|
-16.1%
|
12.5%
|
Price to Book
|
0.79
x
|
0.92
x
|
2.25
x
|
0.88
x
|
1.17
x
|
-99
x
|
Nbr of stocks (in thousands)
|
2,00,927
|
2,35,340
|
2,35,540
|
2,89,115
|
3,19,902
|
3,45,796
|
Reference price
2 |
0.1150
|
0.1150
|
0.2300
|
0.0760
|
0.0780
|
0.0300
|
Announcement Date
|
27/09/18
|
29/08/19
|
27/08/20
|
26/08/21
|
29/08/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5.958
|
2.553
|
-
|
0.035
|
2.128
|
2.132
|
EBITDA
1 |
-3.235
|
-3.939
|
-5.824
|
-6.612
|
-7.847
|
-7.096
|
EBIT
1 |
-3.274
|
-3.983
|
-5.881
|
-6.658
|
-7.9
|
-7.141
|
Operating Margin
|
-54.95%
|
-156.01%
|
-
|
-19,022.86%
|
-371.24%
|
-334.94%
|
Earnings before Tax (EBT)
1 |
-4.301
|
-5.994
|
-7.415
|
-9.504
|
-8.759
|
-20.88
|
Net income
1 |
-2.685
|
-4.35
|
-5.636
|
-7.26
|
-6.641
|
-22.52
|
Net margin
|
-45.07%
|
-170.39%
|
-
|
-20,742.86%
|
-312.08%
|
-1,056.47%
|
EPS
2 |
-0.0170
|
-0.0215
|
-0.0239
|
-0.0253
|
-0.0218
|
-0.0683
|
Free Cash Flow
1 |
-1.529
|
-3.225
|
-1.378
|
-2.621
|
-4.266
|
1.473
|
FCF margin
|
-25.67%
|
-126.33%
|
-
|
-7,487.86%
|
-200.45%
|
69.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/09/18
|
29/08/19
|
27/08/20
|
26/08/21
|
29/08/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
1.5
|
1.37
|
Net Cash position
1 |
7.57
|
7.68
|
3.22
|
4.76
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.191
x
|
-0.1926
x
|
Free Cash Flow
1 |
-1.53
|
-3.23
|
-1.38
|
-2.62
|
-4.27
|
1.47
|
ROE (net income / shareholders' equity)
|
-10.6%
|
-14.8%
|
-21%
|
-29.6%
|
-28.7%
|
-212%
|
ROA (Net income/ Total Assets)
|
-6.15%
|
-6.71%
|
-10.2%
|
-12%
|
-14.7%
|
-23%
|
Assets
1 |
43.68
|
64.86
|
55.12
|
60.59
|
45.2
|
98.14
|
Book Value Per Share
2 |
0.1400
|
0.1300
|
0.1000
|
0.0900
|
0.0700
|
-0
|
Cash Flow per Share
2 |
0.0400
|
0.0400
|
0.0300
|
0.0300
|
0.0100
|
0.0100
|
Capex
1 |
0.07
|
0.04
|
0.04
|
0.07
|
0.05
|
0.01
|
Capex / Sales
|
1.14%
|
1.68%
|
-
|
208.57%
|
2.3%
|
0.28%
|
Announcement Date
|
27/09/18
|
29/08/19
|
27/08/20
|
26/08/21
|
29/08/22
|
29/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +54.55% | 15.2M | | +23.13% | 52.73B | | +37.49% | 39B | | -8.73% | 38.52B | | +28.09% | 30.38B | | -12.26% | 26.39B | | +10.57% | 26.08B | | +45.05% | 14.15B | | +32.23% | 12.6B | | -6.56% | 11.51B |
Other Biotechnology & Medical Research
|